This page contains a Flash digital edition of a book.
44.


45. 46. 47. 48.


49. 50.


51. 52.


53. 54.


55. 56.


59. 60.


61. 62. 63.


64. 65.


66. 67. 68. 69.


58. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992; 14: 309-17.


Benchimol EI, To T, Griffiths AM et al. Outcomes of pediatric inflammatory bowel disease:


THE IMPACT OF INFLAMMATORY BOWEL DISEASE IN CANADA 90


Nugent Z, Blanchard JF, Bernstein CN. A population-based study of health-care resource use among infliximab users. Am J Gastroenterol 2010; 105: 2009-16.


Canadian Institute for Health Information [CIHI] (2010). National Health Expenditure Trends: 1975-2010. Canadian Institute for Health Information. www.cihi.ca.


Third-party payers an average of $19,000 to $22,000 a year per patient, according to the drug’s developer, Centocor Inc (Jenssen in Canada).


Bernstein CN, Longobardi T, Finlayson G et al. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis 2011;


IMS Brogan Inc. Pharmastat Prescription Database. Ottawa, 2012. Data on file.


Sandborn WJ, Rutgeerts P, Feagan BG et al. Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from Act 1 and Act 2. Gut 2007; 56 (Suppl III): A26.


Jewell DP, Satsangi J, Lobo A et al. Infliximab use in Crohn’s disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005; 17: 47-52.


Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol 2002; 35: 151-6.


Lichtenstein GR, Yan S, Bala M et al. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. AM J Gastroenterol 2003; 91-6.


57. Feagan BG, Vreeland MB, Larson LR et al. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol 2000; 95: 1955-60.


Gibson PR, Weston AR, Shann A et al. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn’s disease. J Gastroenterol Hepatol 2007; 22: 1306-12.


Bassi A, Dodd S, Williamson P et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471-8.


Hilsden RJ, Verhoef MJ, Best A et al. A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol 2003; 3: 10.


Silverstein MD, Loftus EV, Sandborn WJ et al. Clinical course and costs of car for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterol 1999; 117: 49-57.


Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol 2007; 21: 507-11.


Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroent and Hep 2008; 6: 41-5.


Hoie O, Schouten LJ, Wolters FL et al. Ulcerative colitis: no rise in mortality in a European-wide population based cohort ten years after diagnosis. Gut 2007; 56: 497-503.


Jess T, Gamborg M, Matzen P et al. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterology 2005; 100: 2724-9.


Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 2—6; 23: 1097-104.


Jess T, Riis L, Vind I et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13: 481-9.


Hutfless SM, Weng X, Liu L et al. Mortality by medication use among patients with inflammatory bowel disease. Gastroenterology 2007; 133: 1779-86.


Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn’s disease. Aliment Pharmacol Ther 2007; 25: 861-70.


Crohn’s and Colitis Australia. The economic costs of Crohn’s disease and ulcerative colitis. June, 2007. www.crohnsandcolitis.com.au.


Benchimol EI, Fortinsky KJ, Gozdyra P et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17: 423-439.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96